Financial Data and Key Metrics Changes - Illumina reported Q4 revenue of $1.16 billion, up 5% year-over-year on a reported basis and 4% on a constant currency basis [20][22] - Non-GAAP EPS for Q4 was $1.35, growing approximately 42% year-over-year, exceeding guidance [26] - Non-GAAP operating margin was 23.7% in Q4, expanding 400 basis points year-over-year [25] Business Line Data and Key Metrics Changes - Clinical consumables revenue grew 20% year-over-year in Q4, driven by increased adoption of sequencing-based diagnostic tests [5][8] - Sequencing consumables revenue was $755 million, up 8% year-over-year, with 11% growth excluding China [22] - Research and applied markets consumable sales were roughly flat year-over-year, reflecting ongoing uncertainty in the funding environment [22] Market Data and Key Metrics Changes - Greater China revenue was $55 million, representing a $25 million decline from Q4 of 2024 [22] - Clinical market maintained momentum, growing 20% outside of China, driven by broader adoption of NGS-based testing [22] - Total sequencing GB output grew at a rate of more than 30% year-over-year, primarily from clinical customers [24] Company Strategy and Development Direction - Illumina's strategy focuses on three pillars: core sequencing, scaling multi-omics, and expanding service data and software capabilities [10][13] - The acquisition of SomaLogic is expected to enhance Illumina's position in the proteomics market, integrating capabilities for deeper biological insights [12] - The company aims to introduce new technologies, including spatial transcriptomics and constellation map read technology, in 2026 [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the momentum built in 2025, expecting organic revenue growth of 2%-4% in 2026, excluding China [17][30] - Clinical consumables are projected to grow double-digit to mid-teens in 2026, while research consumables are expected to decline mid-to-high single digits [30][31] - Management highlighted the importance of adapting to the evolving market dynamics and customer needs, particularly in the clinical space [16][70] Other Important Information - Illumina returned approximately $740 million to shareholders through share repurchases in 2025 [7] - The company ended Q4 with approximately $1.63 billion in cash and cash equivalents [28] - The acquisition of SomaLogic was completed for an upfront payment of $350 million, with potential royalties and milestone payments [27] Q&A Session Summary Question: Operating margin guidance and capital deployment - Management confirmed that the guidance includes an assumption of ending the year at 26%-27% operating margin and discussed capital deployment priorities [36][38] Question: Clinical performance guidance for 2026 - Management explained that the guidance reflects a cautious approach, considering uncertainties in the research environment, but remains optimistic about clinical growth [42][45] Question: Instrumentation split between research and clinical - Management indicated that over 60% of NovaSeq X placements were to clinical customers, with expectations for this trend to continue [50][52] Question: Growth drivers in oncology and genetic applications - Management noted that oncology remains the main growth driver, with increasing use of genetic profiling for various diseases [66] Question: Competitive landscape and pricing strategies - Management expressed confidence in Illumina's competitive position and the ability to address market segments with different pricing strategies [74][76] Question: China market assumptions and BioInsight monetization - Management discussed ongoing conversations with Chinese regulators and the potential for growth in the BioInsight business, emphasizing its early-stage momentum [80][81]

Financial Data and Key Metrics Changes - Illumina reported Q4 2025 revenue of $1.16 billion, a 5% increase year-over-year on a reported basis and 4% on a constant currency basis [20][22] - Non-GAAP EPS for Q4 was $1.35, reflecting a 42% year-over-year growth [26] - Non-GAAP operating margin expanded to 23.7%, up 400 basis points year-over-year [25] Business Line Data and Key Metrics Changes - Clinical consumables revenue grew 20% in Q4 2025, excluding China, driven by increased adoption of sequencing-based diagnostic tests [5][8] - Sequencing consumables revenue reached $755 million, an 8% increase year-over-year [22] - Research and applied markets consumable sales were roughly flat year-over-year, indicating a stabilization compared to previous quarters [22] Market Data and Key Metrics Changes - Greater China revenue was $55 million, down $25 million from Q4 2024, reflecting ongoing export restrictions [22] - Clinical market growth outside of China was 20%, driven by broader adoption of NGS-based testing [22] - Total sequencing GB output grew over 30% year-over-year, primarily from clinical applications [24] Company Strategy and Development Direction - Illumina's strategy focuses on three pillars: core sequencing, scaling multi-omics, and expanding service data and software capabilities [10][12] - The acquisition of SomaLogic is expected to enhance Illumina's position in the proteomics market, integrating capabilities for deeper biological insights [11][12] - The company aims to introduce new technologies, including spatial transcriptomics and constellation map read technology, in the first half of 2026 [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the momentum built in 2025, expecting organic revenue growth of 2%-4% in 2026, excluding China [17][30] - Clinical consumables are projected to grow double-digit to mid-teens in 2026, while research consumables are expected to decline mid- to high-single digits [30][31] - Management highlighted the importance of adapting to the evolving funding environment in the research sector [44] Other Important Information - The company returned approximately $740 million to shareholders through share repurchases in 2025 [7] - Illumina ended Q4 with approximately $1.63 billion in cash and cash equivalents [28] - The company plans to continue share repurchases opportunistically, with $643 million remaining on its authorization [27] Q&A Session Summary Question: Operating margin guidance and capital deployment - Management confirmed that the guidance includes an assumption of ending the year at 26%-27% operating margin and remains committed to long-term margin targets despite the SomaLogic acquisition [36][38] Question: Clinical performance guidance for 2026 - Management explained that the guidance reflects a cautious approach, considering uncertainties in the research environment, but remains optimistic about clinical growth momentum [42][45] Question: Instrumentation split between research and clinical - Management indicated that over 60% of Q4 instrument placements were clinical, with expectations for this trend to continue into 2026 [50][52] Question: Growth drivers in oncology and genetic applications - Management noted that oncology remains the main growth driver, with increasing use of genetic profiling for various applications [66] Question: Competitive landscape and pricing strategies - Management expressed confidence in Illumina's competitive position and highlighted ongoing discussions with customers regarding pricing and workflow efficiencies [74][76]

Financial Data and Key Metrics Changes - In Q4 2025, Illumina's revenue reached $1.16 billion, reflecting a 5% year-over-year increase on a reported basis and a 4% increase on a constant currency basis [18][19] - Non-GAAP EPS for Q4 was $1.35, growing approximately 42% year-over-year, exceeding guidance [24] - Non-GAAP operating margin was 23.7% in Q4, expanding 400 basis points year-over-year [23] Business Line Data and Key Metrics Changes - Clinical consumables revenue grew 20% year-over-year in Q4, driven by increased adoption of sequencing-based diagnostic tests [4][19] - Sequencing consumables revenue was $755 million, up 8% year-over-year, with a notable 11% increase excluding China [19] - Sequencing instruments revenue was approximately flat year-over-year at $154 million, with strong placements of NovaSeq X [22] Market Data and Key Metrics Changes - Greater China revenue was $55 million, down $25 million from Q4 2024, reflecting export restrictions [19] - Clinical market outside China grew 20%, driven by broader adoption of NGS-based testing [19] - Research and applied markets saw consumable sales remain roughly flat year-over-year, indicating ongoing uncertainty in the funding environment [20] Company Strategy and Development Direction - Illumina's strategy focuses on three pillars: core sequencing, scaling multi-omics, and expanding service data and software capabilities [9][12] - The acquisition of SomaLogic is expected to enhance Illumina's position in the proteomics market, integrating capabilities to accelerate innovation [10][11] - The company aims to introduce new technologies, including spatial transcriptomics and constellation map read technology, in the first half of 2026 [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the momentum built in the second half of 2025, expecting organic revenue growth of 2%-4% in 2026, excluding China [15][27] - Clinical consumables are projected to grow double-digit to mid-teens in 2026, while research consumables are expected to decline mid- to high-single digits [15][29] - Management highlighted the importance of adapting to evolving market dynamics and customer needs, particularly in the context of multi-omics [14][78] Other Important Information - The company returned approximately $740 million to shareholders through share repurchases in 2025 [5] - Illumina ended Q4 with approximately $1.63 billion in cash and cash equivalents, maintaining a strong balance sheet [25] - The company plans to change geographical reporting segments starting in Q1 2026 to better align with its commercial structure [31] Q&A Session Summary Question: Operating margin guidance and capital deployment - Management confirmed that the guidance includes an assumption of ending the year at 26%-27% operating margin and remains committed to long-term margin targets despite the SomaLogic acquisition [33][36] Question: Clinical performance guidance for 2026 - Management explained that the guidance reflects continued momentum in clinical growth, with expectations for mid-teens growth, while acknowledging challenges in the research environment [40][42] Question: Instrumentation split between research and clinical - Over 60% of Q4 instrument placements were clinical, with expectations for this trend to continue into 2026 [46][48] Question: Growth drivers in oncology and genetic applications - Oncology is expected to remain the main growth driver, with significant uptake in genetic profiling for various diseases [62][64] Question: BioInsight monetization strategy - Management outlined plans for monetizing BioInsight through specialized data and subscription-based models, indicating a multi-year opportunity [78][79]

Key Takeaways Illumina reports Q4 results on Feb. 5, with EPS estimated at $1.26, up 46.5% YoY.Illumina's NovaSeq X and MiSeq i100 adoption likely boosted high and low-throughput sequencing revenues.New multiomic products and strategic partnerships may have further supported Illumina's Q4 revenues.Illumina, Inc. (ILMN) is set to release fourth-quarter 2025 results on Feb. 5, after the closing bell.The company posted adjusted earnings per share (EPS) of $1.34 in the last reported quarter, which surpassed the ...

44th Annual J.P. Morgan Healthcare Conference Jacob Thaysen, PhD Chief Executive Officer January 13, 2026 © 2026 Illumina, Inc. All rights reserved. © 2026 Illumina, Inc. All rights reserved. Cautionary Notes On Forward Looking Statements This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: J.P. Morgan Healthc ...

Core Insights - Illumina reported Q3 2025 revenue of $1.084 billion, flat year-over-year, slightly above market expectations, with clinical applications driving growth outside of China [1][3] - The company raised its full-year earnings forecast to a range of $4.27 billion to $4.31 billion, an increase of $200 million from previous guidance [12][33] - Illumina's stock surged by 24.76% following the positive earnings report and upward revision of guidance, reversing a downward trend [1][3] Financial Performance - Total revenue: $1.084 billion (year-over-year flat, constant currency flat) [3] - Product revenue: $927 million, up 1.4% year-over-year [3] - Service and other revenue: $157 million, down 5.4% year-over-year [3] - GAAP operating margin: 21.0%, Non-GAAP operating margin: 24.5% [3] - GAAP net income: $150 million, Non-GAAP net income: $206 million [3] - Earnings per share (EPS): GAAP $0.98, Non-GAAP $1.34 [3] - Operating cash flow: $284 million, free cash flow: $253 million [3] - Share repurchase: 1.2 million shares for a total of $120 million at an average price of $97.10 [3] Product and Technology Developments - Illumina launched several new products and technologies, including the 5-base Solution, Constellation Mapped Read, BioInsight, TruSight Oncology Comprehensive, and Illumina Protein Prep [3][4] - The company is extending its strategy from genomic sequencing to multi-omics and proteomics [4] Market and Regulatory Dynamics - The Chinese market is still affected by export restrictions and the "unreliable entity list," but Illumina achieved growth in other regions [5][22] - The company is focused on optimizing global supply and cost structures to mitigate geopolitical risks [5] Detailed Performance Analysis - NovaSeq X platform showed strong performance with over 55 units installed in Q3, aligning with the target of 50 to 60 units per quarter [15][19] - Approximately 78% of testing samples and 51% of revenue were generated through the X platform, indicating a rising conversion rate from NovaSeq 6000 to NovaSeq X [18][25] - Clinical market revenue from sequencing consumables grew at a double-digit rate year-over-year [20] Future Strategy - Illumina's strategic direction includes developing core sequencing business, accelerating X platform transition, and expanding multi-omics [28] - The company has made significant progress in these areas, including the launch of the Illumina Protein Prep product and the establishment of BioInsight for genomic data applications [31][32]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was reported at $1.08 billion, reflecting a year-over-year growth of approximately 2% excluding China, and was above the guidance range [6][18] - Non-GAAP operating margin expanded by 190 basis points to 24.5%, and non-GAAP diluted EPS increased to $1.34, representing an 18% year-over-year growth [18][24] - Greater China revenue was $52 million, with overall revenue growth outside of China being a significant milestone [18][25] Business Line Data and Key Metrics Changes - Sequencing consumables revenue was $747 million, roughly flat year-over-year, but up about 3% excluding China [18][22] - Clinical business saw double-digit revenue growth outside of China, driven by comprehensive genomic profiling and sequencing-intensive applications [18][22] - Research consumable sales declined by high single digits outside of China due to funding uncertainty and pricing dynamics [18][22] Market Data and Key Metrics Changes - The transition to the NovaSeq X platform progressed significantly, with approximately 78% of volumes and 51% of revenue in Q3 being sequenced on X [19][20] - Total sequencing GB output on connected high and mid-throughput instruments grew at a rate of more than 30% year-over-year, primarily driven by clinical demand [21] - The instruments business in Greater China experienced a decline of approximately 54% due to export restrictions [22] Company Strategy and Development Direction - The company is focusing on three strategic pillars: growing the core sequencing business, scaling into multi-omics, and expanding services, data, and software capabilities [9][12] - The launch of Illumina Protein Prep and the five-base solution are part of the strategy to enhance multi-omics capabilities [11][12] - The company aims to achieve high single-digit revenue growth and 20% non-GAAP operating margins by 2027, excluding Greater China [16][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the clinical business as the primary driver of revenue growth, with expectations for a gradual return to growth in the research segment [15][16] - The company remains cautious about the regulatory environment in China but is encouraged by the resilience shown in that market [31] - Management highlighted the importance of customer feedback in shaping future product offerings and maintaining competitive advantage [14][45] Other Important Information - The company has increased its revenue guidance for Greater China by $20 million to approximately $220 million for the year [25] - Non-GAAP operating margin guidance has been raised by approximately 60 basis points to a range of 22.75% to 23% [26] - The company ended the quarter with approximately $1.28 billion in cash and cash equivalents, with plans for continued share repurchases [24] Q&A Session Summary Question: Insights on China and 2026 outlook - Management is pleased with performance in China despite unresolved regulatory issues and is optimistic about customer relationships [30][31] Question: 2026 revenue growth framework - Management acknowledges the potential for low single-digit revenue growth in 2026, driven by clinical growth and muted research revenue [32][34] Question: Margin outlook and operational efficiency - Management is confident in further margin expansion due to disciplined cost management and operational improvements [33][35] Question: Consumables growth and market dynamics - The growth in consumables was primarily driven by clinical demand, with no significant pull forward from academic or government segments [37][38] Question: Competitive landscape and market pressures - Management views competition positively, emphasizing Illumina's multi-dimensional value proposition over single-dimensional competition [44][45] Question: Future instrument placements and market trends - Management expects stable instrument placements moving forward, supported by ongoing demand in clinical and research applications [46][47] Question: Research market dynamics and funding predictability - Management notes that predictability in grant funding is crucial for research spending, with ongoing monitoring of the funding environment [60]

Financial Performance - Illumina's Q3 2025 revenue was $1.08 billion, approximately flat year-over-year in constant currency and reported terms[8] - Non-GAAP operating margin was 24.5%[8] - Non-GAAP diluted EPS reached $1.34, an 18% increase[8, 31] - Free cash flow for Q3 2025 was $253 million[33, 34, 35] Revenue Breakdown - Sequencing consumables revenue was $747 million, a 1% increase[16] - Sequencing instruments revenue was $107 million, a 3% increase[28] - Sequencing service and other revenue was $147 million, a 2% decrease[28] - Revenue excluding Greater China grew by approximately 2% year-over-year in constant currency[8] Regional Performance - Americas revenue was $612 million, a 1% increase[8] - Europe revenue was $309 million, a 6% increase[8] - AMEA (Asia Pacific, Middle East and Africa) revenue was $111 million, a 6% increase[8] - Greater China revenue was $52 million, a 31% decrease[8] NovaSeq X Transition - Over 50% of high-throughput revenue was attributed to NovaSeq X[8, 13, 21] - Over 75% of high-throughput gigabases shipped were attributed to NovaSeq X[13, 21] FY25 Guidance - Illumina anticipates full year 2025 revenue growth between 0% and 1% for the rest of the world and between -1.5% and -0.5% for Greater China[37] - The company projects full year revenue between $427 billion and $431 billion[37]

Core Insights - Illumina reported Q3 2025 financial results that exceeded guidance for revenue and earnings, driven by growth in the clinical segment, marking a return to growth outside of China [2][9]. Financial Performance - Revenue for Q3 2025 was $1,084 million, flat compared to Q3 2024 [9]. - GAAP operating margin was 21.0%, while non-GAAP operating margin was 24.5% for Q3 2025 [9][22]. - GAAP diluted EPS was $0.98, and non-GAAP diluted EPS was $1.34 for Q3 2025 [9][22]. - Net income for Q3 2025 was $150 million, down from $642 million in Q3 2024 [9][24]. Cash Flow and Expenditures - Cash flow from operations was $284 million, compared to $316 million in the prior year [3][20]. - Free cash flow for Q3 2025 was $253 million, down from $284 million in the prior year [3][20]. - Capital expenditures for the quarter were $31 million [3]. Guidance and Outlook - The company expects a total revenue decline in the range of (1.5%) to (0.5%) for fiscal year 2025, an improvement from the previous range of (2.5%) to (1.5%) [9]. - Revenue growth outside of China is projected to be between 0.5% and 1.5% on a constant currency basis [9]. - Non-GAAP operating margin guidance has been raised to a range of 22.75% to 23% [9]. Recent Developments - Illumina launched several new products and initiatives, including a 5-base solution for genomic insights and BioInsight for technology-driven discovery [10]. - The company expanded its personalized cancer care efforts through new pharmaceutical partnerships [10].

Core Insights - Illumina has established a new business unit called BioInsight, focusing on large project contracting, data sharing platforms, and the development of multi-omics AI tools to enhance sequencing business integration and intelligence upgrades [1][2] Group 1: New Business Unit - The new business unit BioInsight will be divided into three main areas: national large project contracting, building a data sharing platform, and developing AI tools for strategic partners and multi-omics analysis [1] - Rami Mehio, previously the global software and IT head at Edico Genome, has been appointed as the General Manager of BioInsight [2] Group 2: Market Challenges - Illumina faces significant challenges globally, including technological competition from emerging sequencing companies, a highly competitive market environment, poor financial performance, and management instability [2] - In the Chinese market, Illumina's challenges are particularly pronounced, having been placed on the "unreliable entity list" in February 2025, which has closed export channels for core equipment to China [2] - In 2024, Illumina's revenue in the Greater China region declined by 16% year-on-year, with market share dropping from 59% in 2020 to approximately 12.36% in the first three quarters of 2024, leading many commercial users to switch to domestic sequencing instruments [2]